Research & Development

Research & Development

EMCM cooperates with global companies and works with various European and national universities in Research & Development in projects to increase the depth of our existing portfolios.

We continue to enhance our existing products and expand their distribution in global markets through innovation and research.


An anti-adhesive gel that prevents the formation of postoperative adhesions without any adverse effects on wound healing, is being developed.

Rebasol’s composition is innovative. It is a bioresorbable product consisting of ultrapure alginate and poly-dextran sulphate. The muco-adherent properties of the gel allow it to remain in place even in gravitationally dependent areas. The product is intended for easy application in both laparotomy and laparoscopy procedures and will be able to achieve a broad coverage of anatomic sites to prevent postoperative adhesion formation.

Preclinical Animal study data

Preclinical animal experimental studies performed with Rebasol gel indicates its efficacy in preventing adhesion formation and also its safety in regards to use of the gel on the presences of anastomosis.

Prevention of postsurgical adhesions using an ultrapure alginate-based gel.
Chaturvedi AA, Lomme RM, Hendriks T, van Goor H.
Br J Surg. 2013 Jun;100(7):904-10. doi: 10.1002/bjs.9131.
PMID: 23592329

Ultrapure alginate gel reduces adhesion reformation after adhesiolysis.
Chaturvedi AA, Lomme RM, Hendriks T, van Goor H.
Int J Colorectal Dis. 2014 Nov;29(11):1411-6. doi: 10.1007/s00384-014-2009-5.
PMID: 25213585

Ultrapure alginate anti-adhesion gel does not impair colon anastomotic strength.
Chaturvedi AA, Lomme RM, Hendriks T, van Goor H.
J Surg Res. 2014 Jun 4. pii: S0022-4804(14)00548-4. doi: 10.1016/j.jss.2014.05.085.
PMID: 24980857

Manufacturing of cell suspensions for renal cell carcinoma

EMCM was requested to manufacture single cell suspensions in an aseptic environment.

The product is a cell therapy for patients affected with late stage renal cell carcinoma. EMCM has played a significant role in the testing, feasibility, method development, and process validations. EMCM complies with relevant GMP licenses and has a “ready-state” aseptic cleanroom in place for the manufacturing of this autologous tumor vaccine. The legal manufacturer updated the Investigational Medicinal Product Dossier to initiate a new clinical trail study within the Netherlands.

Xenograft for dental and orthopaedic applications

EMCM has developed a dental membrane for a global leader in the dental market.

The membrane is to provide a barrier between soft and hard tissue. The product is derived from an animal source and is processed into a decellularised as well as delipidised sterile product for dental application. EMCM has incorporated a novel approach for cleaning and sterilisation of this membrane which involves supercritical carbon dioxide (scCO2). Currently, the manufacturing process is brought to a higher level by the transfer from a feasibility run to a validated manufacturing process.The product is well received in the market due to its excellent properties and demand is rapidly increasing.